A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Bavituximab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Sponsors Peregrine Pharmaceuticals
- 08 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Feb 2016 Status changed from planning to not yet recruiting as per ClinicalTrials.gov record.
- 13 Jan 2016 New trial record